Previous 10 | Next 10 |
2023-09-11 07:28:46 ET More on Madrigal Pharmaceuticals Seeking Alpha’s Quant Rating on Madrigal Pharmaceuticals Historical earnings data for Madrigal Pharmaceuticals Financial information for Madrigal Pharmaceuticals Madrigal's Resmetirom Nears Commer...
CONSHOHOCKEN, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Bill Sibold has succeeded Paul Friedman, M.D., as Chief Executiv...
2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...
2023-08-24 07:41:04 ET Summary Akero Therapeutics is a biopharmaceutical company focused on developing therapies for nonalcoholic steatohepatitis (NASH). NASH is a severe form of non-alcoholic fatty liver disease that can lead to liver failure and other serious health complication...
2023-08-23 06:40:00 ET By some estimates, the market for nonalcoholic steatohepatitis (NASH) medicines will be worth a startling $108 billion by 2030, even though no drugs are yet on the market for it. That makes it a juicy target for small biotech companies looking to develop the next big ...
2023-08-20 10:27:39 ET Summary Madrigal Pharmaceuticals is developing resmetirom, a drug for non-alcoholic steatohepatitis and fatty liver disease, with promising trial results. Madrigal has a strong cash position and manageable debt, but faces rising R&D costs and competition...
2023-08-14 13:19:20 ET Despite recent setbacks, drugmakers are still forging ahead in their quest to develop effective treatments for non-alcoholic steatohepatitis, or NASH, a growing public health concern that could represent a roughly $108B global market opportunity by 2030. According...
2023-08-10 13:48:08 ET Summary 89bio, Inc. is a clinical-stage biotech company focused on developing therapies for liver and cardio-metabolic diseases. The stock surged after top-line data from a Phase 2 study for its primary drug candidate targeting NASH came out in March. Th...
2023-08-10 12:49:41 ET Summary Madrigal's declining share price may be justified by external developments relating to the NASH market. Insurer and FDA commentary suggest an uphill battle to commercialize Resmetirom. The advent and widespread usage of GLP-1 weight loss drug thr...
2023-08-08 09:00:05 ET Madrigal Pharmaceuticals press release ( NASDAQ: MDGL ): Q2 GAAP EPS of -$4.69. As of June 30, 2023, Madrigal had cash, cash equivalents and marketable securities of $298.4 million, compared to $358.8 million at December 31, 2022. Interest inco...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...